Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Infliximab Dose Escalation in Pediatric IBD
NCT02566889Phase 4Terminated
- Sponsor
- Janssen Scientific Affairs
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of infliximab in Crohn's disease, ulcerative colitis (UC), sponsored by Janssen Scientific Affairs. Started Apr 2016; status: terminated.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02566889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566889.